Fibrates and coronary heart disease reduction in diabetes

Current Opinion in Endocrinology and Diabetes

Volumn 9, Issue 4, 2002, Pages 312-322

  Robins, Sander J ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CERIVASTATIN; CLOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL;

BODY WEIGHT; DIABETES MELLITUS; DIGESTIVE SYSTEM FUNCTION DISORDER; DYSLIPIDEMIA; FIBRINOLYSIS; GALLSTONE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LIVER TOXICITY; METABOLIC SYNDROME X; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; RHABDOMYOLYSIS; RISK FACTOR;

EID: 0036705773     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200208000-00004     Document Type: Review

References (116)

1. Group of Physicians of the Newcastle upon Tyne Region. Trial of clofibrate in the treatment of ischemic heart disease. BMJ 1971, 4:767-775.
2. Research Committee of the Scottish Society of Physicians. Ischemic heart disease: A secondary prevention trial using clofibrate. BMJ 1971;4:775-784.
3. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381.
4. Committee of Principal Investigators. A co-operative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J 1978;40:1069-1118.
5. Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-1245.
6. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223:405-418.
7. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410-418.
8. The BIP Study Group. Secondary prevention by raising HDL-chotesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000, 102:21-27. A large, placebo-controlled clinical trial that showed in contrast to VA-HIT that a fibrate did not reduce CHD events. However, the population recruited for BIP had fewer diabetics and an overall lower body weight (consistent with less insulin resistance) than in VA-HIT.
9. Ericsson C-G, Hamsten A, Nilsson J, et al.: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996, 347:849-853.
10. Syvanne M, Nieminen MS, Frick MH, et al.: Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation 1998, 98:1993-1999.
11. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 2001, 357:905-910. This angiographic trial with the acronym DAIS, thus far the only coronary intervention trial which has exclusively recruited subjects with diabetes, found a significant reduction in coronary artery narrowing with a fibrate therapy compared with placebo.
12. Johnson CL, Rifkind BM, Sempos CT, et al.: Declining serum chotesterol levels among US adults. The National Health and Nutrition Examination Surveys. JAMA 1993, 269:3002-3008.
13. Genest J Jr, McNamara JR, Ordovas JM, et al.: Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992, 19:792-802.
14. Rubins HB, Robins SJ, Collins D, et al.: Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol 1995, 75:1196-1201.
15. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009.
16. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979, 2:154-160.
17. Despres J-P, Lamarche B, Mauriege P, et al.: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952-957.
18. Lempiainen P, Mykkanen L, Pyorala K, et al.: Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999, 100:123-128.
19. Lakka HM, Lakka TA, Tuomilehto J, et al.: Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men. The Kuopio ischemic heart disease risk factor study. Arch Intern Med 2000, 160:1160-1168.
20. Petersen LA, Normand ST, Leape LL, et al.: Comparison of use of medications after acute myocardial infarction in the Veterans Health Administration and Medicare. Circulation 2001, 104:2898-2904.
21. Kleinman JC, Donahue RP, Harris MI, et al.: Mortality among diabetics in a national sample. Am J Epidemiol 1988, 128:389-401.
22. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999, 281:1291-1297.
23. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
24. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
25. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2001, 24 (suppl 1):S58-S61.
26. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999, 10:245-257.
27. Pineda Torra I, Chinetti G, Dural C, et al.: Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Opin Lipidol 2001, 12:245-254.
28. Vu-Dac N, Schoonjans K, Laine B, et al.: Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 1994, 269:31012-31018.
29. Vu-Dac N, Schoonjans K, Kosykh V, et al.: Fibrates increase human apolipoprotein A-II expression through activation of peroxisome proliferator-activated receptor. J Clin Invest 1995, 96:741-750.
30. Schoonjans K, Staels B, Deeb S, et al.: Fibrates and fatty acids induce lipoprotein lipase gene expression via the peroxisome proliferator activated receptors. Circulation 1995, 92/8 (Suppl 1):1-495.
31. Chinetti G, Lestavel S, Bocher V, et al.: PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Med 2001, 7:53-58.
32. Chinetti G, Gbaguidi FG, Griglio S, et al.: CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000, 101:2411-2417.
33. Chianale J, Vollrath V, Wielandt AM, et al.: Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem J 1996, 314:781-786.
34. Staels B, Vu-Doc N, Kosykh VA, et al.: Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. J Clin Invest 1995, 95:705-712.
35. Haubenwallner S, Essenburg AD, Barnett BC, et al.: Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J Lipid Res 1995, 36:2541-2551.
36. Post SM, Duez H, Gervois PP, et al.: Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol 2001, 21:1840-1845.
37. Jin F-Y, Kamanna VS, Chuang M-Y, et al.: Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell Pine (Hep G2). Arterioscler Thromb Vasc Biol 1996, 16:1052-1062.
38. Heller F, Harvengt C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol 1983, 25:57-63.
39. Mjos OD, Faergeman O, Hamilton RL, et al.: Characterization of remnants produced during the metabolism of triglyceride-rich lipoproteins of blood plasma and intestinal lymph in the rat. J Clin Invest 1975, 56:603-615.
40. Redgrave TG, Small DM. Quantitation of the transfer of surface phospholipid of chylomicrons to the high density lipoprotein fraction during catabolism of chylomicrons in the rat. J Clin Invest 1979, 64:162-171.
41. Oude Elferink RPJ, Ottenhoff R, van Wijland M, et al.: Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse. J Clin Invest 1995, 95:31-38.
42. Hertz R, Bishara-Shieban J. Mode of action of peroxisome proliferators as hypolipidemic drugs, suppression of apolipoprotein C-III. J Biol Chem 1995, 270:13470-13475.
43. Tilly-Kiesi M, Tikkanen MJ. Low density lipoprotein density and composition in hypercholesterolemic men treated with HMG CoA reductase inhibitors and gemfibrozil. J Intern Med 1991, 229:427-434.
44. McNamara JR, Jenner JL, Li Z, et al.: Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb 1992, 12:1284-1290.
45. Yuan J, Tsai MY, Hunninghake DB. Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis. 1994, 110:1-11.
46. Franceschini G, Lovati MR, Manzoni C, et al.: Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction. Atherosclerosis 1995, 114:61-71.
47. Yoshida H, Ishikawa T, Ayaori M, et al.: Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study. Atherosclerosis 1998, 139:179-187.
48. Bertolotti M, Concari M, Loria P, et al.: Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric derivatives on the rates of cholesterol 7α-hydroxylation in humans. Arterioscler Thromb Vasc Biol 1995, 15:1064-1069.
49. Leiss O, von Bergmann K, Gnasso A, et al.: Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects. Metabolism 1985, 34:74-82.
50. Lundman P, Eriksson M, Schenck-Gustaffson K, et al.: Transient triglyceridemia decreases vascular reactivity in young healthy men without risk factors for coronary heart disease. Circulation 1997, 10:3266-3268.
51. Evans M, Anderson RA, Graham J, et al.: Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 2000, 101:1773-1779.
52. Fujii S, Sobel BE. Direct effects of gemfibrozil on the fibrinolytic system. Diminution of synthesis of plasminogen activator inhibitor type 1. Circulation 1992, 85:1888-1893.
53. Keber I, Lavre J,Suc S, et al.: The decrease of plasminogen activator inhibitor after normalization of triglycerides during treatment with fibrates. Fibrinolysis 1994, 8 (Suppl 2) 57-59.
54. Wilkes HC, Meade TW, Barzegar S, et al.: Gemfibrozil reduces plasma prothrombin fragment F1+2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb Haemostas 1992, 67:503-506.
55. Pazzucconi F, Mannucci L, Mussoni L, et al.: Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia. Eur J Olin Pharmacol 1992, 43:219-223.
56. Navab M, Berliner JA, Subbanagounder G, et al.: HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001, 21:481-488.
57. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21:473-480.
58. Ridker PM, Rifai N, Pfeffer MA, et al.: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol values. Circulation 1998, 98:839-844.
59. Ridker PM, Hennekens OH, Buring JE, et al.: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Meal 2000, 342:836-843.
60. Ridker PM. High sensitivity C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001, 103:1813-1818.
61. Torzewski M, Rist C, Mortensen RF, et al.: C-reactive protein in the arterial intima. Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Circulation 2000, 20:2094-2099.
62. Yudkin JS, Stehouwer CDA, Emeis JJ, et al.: C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999, 19:972-978.
63. Hak AE, Coen DA, Stehouwer MLB, et al.: Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999, 19:1986-1991.
64. Frohlich M, Imhof A, Berg G, et al.: Association between C-reactive protein and features of the metabolic syndrome. Diabetes Care 2000, 23:1835-1839.
65. Lemieux I, Pascot A, Prud'homme D, et al.: Elevated C-reactive protein. Another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001, 21:961-967. This study supports previous observations linking high plasma levels of CRP to obesity but additionally shows with computed tomography that CRP is strongly correlated with abdominal adipose tissue accumulation and plasma insulin levels but not with plasma lipoprotein profiles.
66. Staels B, Koenig W, Habib A, et al.: Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 1998, 393:790-793.
67. Marx N, Mackman N, Schonbeck U, et al.: PPARα activators inhibit tissue factor expression and activity in human monocytes. Circulation 2001, 103:213-219.
68. Neve BP, Corseaux D, Chinetti G, et al.: PPARα agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2001, 103:207-212.
69. Cockerill GW Huehns TY, Weerasinghe A, et al.: Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001, 103:108-112. Strong evidence fo yet another mechanism by which increased plasma levels of HDL may be cardicprotective, by a mechanism blunting the early vascular inflammatory response to cytokines.
70. Ashby DT, Rye KA, Clay MA, et al.: Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol 1998, 18:1450-1455.
71. Sorisky A, Odi TC, Simo IE, et al.: Change in composition of high density lipoprotein during gemfibrozil therapy. Atherosclerosis 1987, 67:181-189.
72. Lewis GF, Uflelman B, Lamarche B, et al.: Production of small high-density lipoprotein particles after stimulation of in vivo lipolysis in hypertriglyceridemic individuals: Studies before and after triglyceride-lowering therapy. Metabolism 1998, 47:234-242.
73. Betteridge DJ. Diabetic dyslipidemia. Am J Med 1994, 96 (suppl 6A):22S-31S.
74. Dunn FL. Plasma lipid and lipoprotein disorders in IDDM. Diabetes 1992, 41 (suppl 2):102-106.
75. Laakso M. Lipids and lipoproteins as risk factors for coronary heart disease in non-insulin-dependent diabetes mellitus. Ann Med 1996, 28:341-345.
76. Lewis GF, O'Meara NM, Soltys PA, et al.: Hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab 1991, 72:934-944.
77. Syvanne M, Vuorinen-Markkola H, Hilden H, et al.: Gemfibrozil reduces post-prandial lipernia in non-insulin-dependent diabetes mellitus. Arterioscler Thromb 1993, 13:286-295.
78. Eckel RH, Yost TJ. Weight reduction increases adipose tissue lipoprotein lipase responsiveness in obese women. J Clin Invest 1987, 80:992-997.
79. Grundy SM, Mok HY, Zech L, et al.: Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. J Clin Invest 1979, 63:1274-1283.
80. Steiner G, Haynes FJ, Yoshino G, et al.: Hyperinsulinemia and in vivo very-low-density lipoprotein-triglyceride kinetics. Am J Physiol 1982, 246:E187-192.
81. Ambrosch A, Muhlen I, Kopf D, et al.: LDL size distribution in relation to insulin sensitivity and lipoprotein pattern in young and healthy subjects. Diabetes Care 1998, 21:2077-2084.
82. Haffner SM, Mykkanen L, Robbins D, et al.: A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects. Diabetologia 1995, 38:1328-1336.
83. Meigs JB, Mittleman MA, Nathan DM, et al.: Hyperinsulinemia, hyperglycemia, and impaired hemostasis. The Framingham Offspring Study. JAMA 2000, 283:221-223.
84. Fichtlscherer S, Rosenberger G, Walter DH, et al.: Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000, 102:1000-1006.
85. Goodfellow J, Ramsey MW, Luddington LA, et al.: Endothelium and inelastic arteries: an early marker of vascular dysfunction in non-insulin dependent diabetes. BMJ 1996, 312:744-745.
86. O'Brien SFO, Watts GF, Playford DA, et al.: Low density lipoprotein size, high lipoprotein concentration and endothelial dysfunction in non-insulin diabetes. Diabet Med 1997, 14:974-978.
87. Arcaro G, Cretti A, Balzano S, et al.: Insulin causes endothelial dysfunction in humans. Sites and mechanisms. Circulation 2002, 105:576-582.
88. Steiner G. Altering triglyceride concentrations changes insulin-glucose relationships in hypertriglyceridemic patients. Diabetes Care 1991, 14:1077-1081.
89. Mussoni L, Mannucci L, Sirtori C, et al.: Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. Atherosclerosis 2000, 148:397-406.
90. Idzior-Walus B, Sieradzki J, Rostworowski W, et al.: Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest 2000, 30:871-878.
91. Jeng C-Y, Sheu WH, Fuh MM, et al.: Gemfibrozil treatment of endogenous hypertriglyceridemia: Effect on insulin-mediated glucose disposal and plasma insulin concentrations. J Clin Endocrinol Metab 1996, 81:2550-2553.
92. Vuorinen-Markkola H, Yki-Jarvinen H, Taskinen MR. Lowering of triglyceridesby gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36:161-169.
93. Riccardi G, Genovese S, Saldamacchia G, et al.: Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes. Atherosclerosis 1989, 75:175-181.
94. Karhapaa P, Uusitupa M, Voutilainen E, et al.: Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia. Clin Pharmacol Ther 1992, 52:620-626.
95. Guerre-Millo M, Gervois P, Raspe E, et al.: Peroxisome proliferator-activated receptor e activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000, 275:16638-16642.
96. Winegar DA, Brown PJ, Wilkison WO, et al.: Effects of fenofibrate on lipid parameters in obese rhesus monkeys. J Lipid Res 2001, 42:1543-1551.
97. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984, 251:351-364.
98. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
99. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998, 279:1615-1622.
100. Blankenhorn DH, Nessim SA, Johnson RL, et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987, 247:3233-3240.
101. Koskinen P, Manttari M, Manninen V, et al.: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992, 15:820-825.
102. Manninen V, Tenkanen L, Koshinen P, et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992, 85:37-45.
103. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 1995, 92:1779-1785.
104. Meigs JB, Nathan DM, Wilson PWF, et al.:. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med 1998, 128:524-533.
105. Robins SJ, Collins D, Rubins HB. Diabetes, hyperinsulinemia, and recurrent coronary events in the VA-High Density Lipoprotein Intervention Trial (VA-HIT). Circulation 2000, 102:II-847. A prespecified analysis showing that CHD reduction with gemfibrozil was almost exclusively confined to a subgroup comprising almost half of the VA-HIT population with a low HDL-C who had either diabetes or hyperinsulinemia without diabetes.
106. Robins SJ, Collins D, Wittes JT, et al.:. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001, 285:1585-1591. Additional analysis from VA-HIT demonstrating that in a multivariate model adjusted for all major CHD risk factors, only the increase in HDL-C with gemfibrozil predicted a reduction in CHD events, but could explain only a relatively small amount of the benefit of therapy.
107. Cushman M, Collins, D, Tracy RP, et al.: Inflammation, gemfibrozil, and coronary heart disease: the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Circulation 2002, 105:86. A substudy from VA-HIT, presented and published to-date only in abstract form but demonstrating that like statins, a fibrate can reduce plasma CRP levels and the reduction in CRP is significantly related to a reduction in CHD events.
108. Goldbourt U, Behar S, Reicher-Reiss H, et al.: for the Bezafibrate Infarction Prevention Study Group. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993, 71:909-915.
109. Heady JA, Morris JN, Oliver MF. WHO clofibrate/cholesterol trial: clarifications. Lancet 1992, 340:1405-1406.
110. Haffner SM, Alexander CM, Cook TJ, et al.: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Arch Intern Med 1999, 159:2661-2667.
111. Goldberg RB, Mellies MJ, Sacks FM, et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation 1998, 98:2513-2519.
112. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357.
113. MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999, 20:725-741.
114. Sacks FM, Tonkin AM, Shepherd J, et al.: Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 2000, 102:1893-1900.
115. MRC/BHF Heart Protection Study. Available at: http://www.ctsu.ox.ac.uk/hps/
116. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Survey. JAMA 2002, 287:356-359.